TNGX (STOCKS)
Tango Therapeutics, Inc.
$12.485000
-0.205000 (-1.62%)
Prev close: $12.690000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Malte Peters
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,705.64M
- Employees
- 155
- P/E (TTM)
- -13.85
- P/B (TTM)
- 8.85
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
7
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$0.14 | $-0.05 | +0.1938 | +360.22% |
|
Jun 2025 (Q2)
|
$-0.35 | $-0.35 | +0.0048 | +1.35% |
|
Mar 2025 (Q1)
|
$-0.36 | $-0.36 | -0.0030 | -0.84% |
|
Dec 2024 (Q4)
|
$-0.35 | $-0.35 | -0.0044 | -1.27% |
Financial Statements
| Revenues | $66.50M |
| Benefits Costs and Expenses | $166.91M |
| Costs And Expenses | $166.91M |
| Nonoperating Income/Loss | $9.93M |
| Operating Expenses | $176.84M |
| Research and Development | $134.00M |
| Other Operating Expenses | $42.84M |
| Operating Income/Loss | -$110.34M |
| Income/Loss From Continuing Operations After Tax | -$100.52M |
| Income/Loss From Continuing Operations Before Tax | -$100.41M |
| Income Tax Expense/Benefit | $108.00K |
| Interest Income/Expense After Provision For Losses | $5.76M |
| Interest Income/Expense Operating, Net | $5.76M |
| Net Income/Loss | -$100.52M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$100.52M |
| Net Income/Loss Available To Common Stockholders, Basic | -$100.52M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$0.91 |
| Diluted Earnings Per Share | -$0.92 |
| Basic Average Shares | 332,045,157 |
| Diluted Average Shares | 338,860,886 |
| Assets | $210.14M |
| Current Assets | $163.78M |
| Cash | $152.80M |
| Other Current Assets | $10.98M |
| Noncurrent Assets | $46.36M |
| Fixed Assets | $7.35M |
| Other Non-current Assets | $39.01M |
| Liabilities | $50.11M |
| Current Liabilities | $18.44M |
| Accounts Payable | $2.23M |
| Wages | $6.48M |
| Other Current Liabilities | $9.74M |
| Noncurrent Liabilities | $31.66M |
| Equity | $160.03M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $160.03M |
| Liabilities And Equity | $210.14M |
| Net Cash Flow From Operating Activities | -$145.82M |
| Net Cash Flow From Operating Activities, Continuing | -$145.82M |
| Net Cash Flow From Investing Activities | $146.91M |
| Net Cash Flow From Investing Activities, Continuing | $146.91M |
| Net Cash Flow From Financing Activities | $4.09M |
| Net Cash Flow From Financing Activities, Continuing | $4.09M |
| Net Cash Flow | $5.19M |
| Net Cash Flow, Continuing | $5.19M |
| Comprehensive Income/Loss | -$101.14M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$101.14M |
| Other Comprehensive Income/Loss | -$193.78M |